Description: Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Home Page: alimerasciences.com
ALIM Technical Analysis
6310 Town Square
Alpharetta,
GA
30005
United States
Phone:
678 990 5740
Officers
Name | Title |
---|---|
Mr. Charles Daniel Myers | Non-Exec. Chairman & Consultant |
Mr. Richard S. Eiswirth Jr. | Pres, CEO, Interim CFO & Director |
Mr. David R. Holland | Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets |
Dr. Philip Ashman Ph.D. | COO & Sr. VP of Commercial Operations - Europe |
Christopher S. Visick | VP, Gen. Counsel & Sec. |
Dr. David Dyer M.D. | Chief Retina Specialist |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 60.6061 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0 |
Price-to-Sales TTM: | 0.2917 |
IPO Date: | 2010-04-22 |
Fiscal Year End: | December |
Full Time Employees: | 145 |